Shares of Guardant Health Inc (NASDAQ:GH) have been given a consensus recommendation of “Buy” by the seven research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $113.50.
Several analysts have recently weighed in on the company. JPMorgan Chase & Co. lifted their target price on Guardant Health from $90.00 to $135.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Canaccord Genuity reiterated a “buy” rating and set a $125.00 target price (up from $96.00) on shares of Guardant Health in a research report on Wednesday, August 7th. Zacks Investment Research downgraded Guardant Health from a “strong-buy” rating to a “hold” rating in a research report on Saturday, August 10th. Finally, Cowen set a $110.00 target price on Guardant Health and gave the stock a “buy” rating in a research report on Wednesday, August 7th.
In related news, Chairman Amirali Talasaz sold 100,000 shares of Guardant Health stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $100.17, for a total value of $10,017,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ian T. Clark sold 9,683 shares of Guardant Health stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $89.75, for a total value of $869,049.25. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 948,306 shares of company stock valued at $94,997,713. Corporate insiders own 13.00% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in GH. Advantage Investment Management LLC raised its holdings in shares of Guardant Health by 200.0% in the second quarter. Advantage Investment Management LLC now owns 450 shares of the company’s stock valued at $39,000 after acquiring an additional 300 shares in the last quarter. HM Payson & Co. purchased a new position in Guardant Health in the second quarter valued at about $43,000. Mascoma Wealth Management LLC purchased a new position in Guardant Health in the first quarter valued at about $54,000. Oppenheimer Asset Management Inc. purchased a new position in Guardant Health in the second quarter valued at about $62,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Guardant Health in the second quarter valued at about $76,000. Hedge funds and other institutional investors own 70.55% of the company’s stock.
Shares of NASDAQ:GH traded down $5.74 on Thursday, hitting $98.62. 1,308,750 shares of the company’s stock were exchanged, compared to its average volume of 1,012,461. Guardant Health has a 12 month low of $27.04 and a 12 month high of $112.21. The stock has a market capitalization of $9.17 billion and a price-to-earnings ratio of -35.22. The business’s 50 day simple moving average is $94.54 and its two-hundred day simple moving average is $77.82.
Guardant Health (NASDAQ:GH) last released its earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.21. Guardant Health had a negative return on equity of 22.93% and a negative net margin of 60.08%. The business had revenue of $53.98 million during the quarter, compared to the consensus estimate of $35.97 million. During the same period last year, the company earned ($1.75) earnings per share. The business’s revenue for the quarter was up 178.5% compared to the same quarter last year. On average, research analysts anticipate that Guardant Health will post -1.27 earnings per share for the current fiscal year.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Read More: What is meant by holder of record?
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.